The DOI matches its Crossref record.
Evaluation of naltrexone for dissociative symptoms in borderline personality disorder
Abstract
Data from a pilot study suggest that naltrexone might reduce dissociative symptoms in patients with borderline personality disorder. However, the interpretation of these data is limited by the lack of a control group and by the nonblind nature of this study. Hence, we examined the effects of naltrexone using a more rigorous design that controlled for major confounders such as spontaneous reduction of dissociation over time and placebo effects. Unmedicated patients with BPD [according to Diagnostic and Statistical Manual of Mental Disorders-IVth edition (DSM-IV)] were included in two small double-blind placebo-controlled randomized trials (total n=29). Patients received both 3 weeks of naltrexone (50 or 200 mg/day) and 3 weeks of placebo in a randomized order. Twenty-five patients completed the study according to protocol. Dissociation under naltrexone and placebo, respectively, was compared by repeated-measures analyses of variance. In either trial, both the intensity and duration of dissociative symptoms were numerically lower under naltrexone than under placebo. However, the effects were too small to reach statistical significance. Our data provide the first estimate of the pure pharmacological antidissociative efficacy of naltrexone from a rigorously designed trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“neither naloxone nor naltrexone performed better than placebo for dissociative symptoms in randomized controlled trials in borderline personality disorder samples [120,121].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [121]
In the citing paper
“neither naloxone nor naltrexone performed better than placebo for dissociative symptoms in randomized controlled trials in borderline personality disorder samples [120,121].”
From Treatment of dissociative identity disorder: leveraging neurobiology to optimize success (2024) · cites this paper as [120]
Citations
Cited by
The aetiology of psychogenic non‐epileptic seizures: risk factors and comorbidities
Popkirov, S., Asadi‐Pooya, A. A., Duncan, R., Gigineishvili, D., Hingray, C., Miguel Kanner, A., LaFrance, W. C., Pretorius, C., Reuber, M., & on behalf of the ILAE PNES Task Force (2019) · Epileptic Disorders · doi:10.1684/epd.2019.1107 · Cited by 195
Pharmacotherapy for Borderline Personality Disorder—Current Evidence and Recent Trends
Stoffers‐Winterling, J., & Lieb, K. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0534-0 · Cited by 129
Self-citationPharmacological interventions for people with borderline personality disorder
Stoffers‐Winterling, J., Storebø, O. J., Ribeiro, J. P., Kongerslev, M., Vӧllm, B., Mattivi, J. T., Faltinsen, E. G., Todorovac, A., Jørgensen, M. S., Edemann-Callesen, H., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012956.pub2 · Cited by 154
Self-citationEndogenous opiates and behavior: 2012
Bodnar, R. J. (2013) · Peptides · doi:10.1016/j.peptides.2013.10.001 · Cited by 116
McKinnon, M. C., Boyd, J. E., Frewen, P. A., Lanius, U. F., Jetly, R., Richardson, J. D., & Lanius, R. A. (2016) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2016.07.017 · Cited by 94
Complex Trauma in Adolescents and Adults
Briere, J., & Scott, C. (2015) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2015.05.004 · Cited by 114
Patients with Borderline Personality Disorder in Emergency Departments
Shaikh, U., Qamar, I., Jafry, F., Hassan, M., Shagufta, S., Odhejo, Y. I., & Ahmed, S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00136 · Cited by 89
“(110) Two double-blind placebo-controlled randomized trials 25 Patients received both 3 weeks of naltrexone (50 or 200 mg/ day) and 3 weeks of placebo in a randomized order The dissociative symptoms were numerically not statistically significant lower under naloxone than placebo”
Timäus, C., Meiser, M., Bandelow, B., Engel, K., Paschke, A. M., Wiltfang, J., & Wedekind, D. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2377-z · Cited by 72
Psychopharmacologic treatment of borderline personality disorder
Ripoll, L. H. (2013) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2013.15.2/lripoll · Cited by 70
A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder
Hancock-Johnson, E., Griffiths, C., & Picchioni, M. (2017) · CNS Drugs · doi:10.1007/s40263-017-0425-0 · Cited by 61
“[19] was rated as a low risk for most sources of bias, apart from allocation concealment (Table 2).”
BackgroundResultInfluentialBozzatello, P., Rocca, P., Rosa, M. L. D., & Bellino, S. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1686482 · Cited by 61
“Among opiate antagonists, naloxone and naltrexone were not found to be superior to placebo in treating acute dissociative states in patients with BPD in two small placebocontrolled studies [110,111].”
BackgroundPharmacotherapy for dissociative disorders: A systematic review
Sutar, R., & Sahu, S. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.112529 · Cited by 42
Borderline Personality Disorder Features and Risk for Prescription Opioid Use Disorders
Tragesser, S. L., Jones, R. E., Robinson, R. J., Stutler, A., & Stewart, A. (2013) · Journal of Personality Disorders · doi:10.1521/pedi_2013_27_094 · Cited by 42
“, 2010), evidence for the effectiveness of the opioid antagonist naltrexone in the treatment of dissociative symptoms in BPD (Bohus et al., 1999; Schmahl et al., 2012), and evidence for higher pain thresholds among individuals with BPD and a history of self-harm (Cárdenas-Morales et al.”
BackgroundPossible role of a dysregulation of the endogenous opioid system in antisocial personality disorder
Bandelow, B., & Wedekind, D. (2015) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2497 · Cited by 41
Collaborative Deprescribing in Borderline Personality Disorder: A Narrative Review
Fineberg, S. K., Gupta, S., & Leavitt, J. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000200 · Cited by 42
Current Clinical Psychopharmacology in Borderline Personality Disorder
CASALE, A. D., Bonanni, L., Bargagna, P., Novelli, F., Fiaschè, F., Paolini, M., Forcina, F., Anibaldi, G., Cortese, F. N., Iannuccelli, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210610092958 · Cited by 32
“… HD, RSA, AWAC The mean rate of heavy drinking days, the rate of serious AEs, and the rate of treatment discontinuation after AEs were significantly higher in BPD. Schmahl et al., 2012 [105] NLT (50 - 200) Randomized Controlled Trial (12) 29 (0, 29) Study 1: 28.3 (8.0); Study…”
BackgroundResultInfluentialNeurotransmitter, neurohormonal, and neuropeptidal function in stress and PTSD
Bremner, J. D., & Pearce, B. R. (2016) · Wiley eBooks · doi:10.1002/9781118356142.ch9 · Cited by 28
Treatment of dissociative identity disorder: leveraging neurobiology to optimize success
Purcell, J. B., Brand, B., Browne, H. A., Chefetz, R. A., Shanahan, M., Bair, Z. A., Baranowski, K. A., Davis, V., Mangones, P., Modell, R. L., et al. (2024) · Expert review of neurotherapeutics · doi:10.1080/14737175.2024.2316153 · Cited by 18
Niedrig dosiertes Naltrexon in der Behandlung dissoziativer Symptome
Pape, W., & Wöller, W. (2015) · Der Nervenarzt · doi:10.1007/s00115-014-4015-9 · Cited by 17
Burback, L., Forner, C. C., Winkler, O., Al-Shamali, H. F., Ayoub, Y., Paquet, J., & Verghese, M. (2024) · Psychology Research and Behavior Management · doi:10.2147/prbm.s402456 · Cited by 16
“121,125 Naltrexone doses ranged from 50 to 250 mg/day, over 3–10 weeks.”
Treatment of dissociative symptoms with opioid antagonists: a systematic review
Escamilla, I., Juan, N., Peñalva, C., Sánchez-Llorens, M., Renau, J., Benito, A., & Haro, G. (2023) · European Journal of Psychotraumatology · doi:10.1080/20008066.2023.2265184 · Cited by 12
The Potential Role of Naltrexone in Borderline Personality Disorder.
Moghaddas, A., Dianatkhah, M., Ghaffari, S., & Ghaeli, P. (2017) · PubMed Central · Cited by 11
Francois, D., Roth, S. D., & Klingman, D. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150803-09 · Cited by 11
Gescher, D. M., Schanze, D., Vavra, P., Wolff, P., Zimmer‐Bensch, G., Zenker, M., Frodl, T., & Schmahl, C. G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02628-z · Cited by 10
“Conversely, opioid antagonists have been shown to reduce BPD-associated symptoms [16, 17] such as NSSI [17], binge eating [17], suicidality [18], and dissociation [19, 20].”
Self-citationDahlberg, S., Chang, E. T., Weiss, S. R., Dopart, P. J., Gould, E. M., & Ritchey, M. E. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s381652 · Cited by 14
Ribeiro, J. P., Juul, S., Kongerslev, M., Jørgensen, M. S., Vӧllm, B., Edemann-Callesen, H., Sales, C. P., Schaug, J. P., Lieb, K., Simonsen, E. H., et al. (2024) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.172 · Cited by 10
Self-citationEnning, F., & Schmahl, C. G. (2021) · Der Nervenarzt · doi:10.1007/s00115-021-01239-1 · Cited by 9
Self-citationTreating Symptoms of Borderline Personality Disorder Through Narrative Therapy and Naltrexone
Tadros, E., Cappetto, M., & Kaur, L. (2019) · American Journal of Family Therapy · doi:10.1080/01926187.2019.1590787 · Cited by 9
Pharmacotherapy of personality disorders: what we know and what we have to search for
Bozzatello, P., Ghirardini, C., Uscinska, M., Rocca, P., & Bellino, S. (2017) · Future Neurology · doi:10.2217/fnl-2017-0010 · Cited by 8
“[96] evaluated oral naltrexone administration in treating dissociative symptoms in BPD in 29 patients who received naltrexone (50 or 200 mg/day) over 3 weeks versus placebo.”
BackgroundRecent evidence-based developments in the treatment of DID
Bachrach, N., & Huntjens, R. J. C. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1650164 · Cited by 10
“…blind randomized controlled trials among individuals with borderline personality disorder found no superiority of naloxone or naltrexone over placebo in reduction of dissociative symptoms (91, 92), and naloxone did not block ketamine-induced dissociation in a double-blind crossover study (93).”
Psychedelic-Associated Depersonalization-Derealization Disorder
Michal, M. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_599 · Cited by 8
Uscinska, M., & Bellino, S. (2018) · Future Neurology · doi:10.2217/fnl-2018-0006 · Cited by 6
Schmahl, C. G., & Bär, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-12783-0_9 · Cited by 1
Self-citationFunctional Neurological Disorder and Dissociative Disorders in Women
Raynor, G., & Baslet, G. C. (2019) · Springer eBooks · doi:10.1007/978-3-030-04245-5_3 · Cited by 4
Farmacotherapie persoonlijkheidsstoornissen
Ingenhoven, T., & Rinne, T. (2017) · Bohn Stafleu van Loghum eBooks · doi:10.1007/978-90-368-0931-3_20 · Cited by 3
Schmeck, K., & Romanos, M. (2023) · Springer eBooks · doi:10.1007/978-3-662-65267-1_20 · Cited by 2
Schmahl, C. G., & Bar, K. J. (2016) · Springer eBooks · doi:10.1007/978-3-662-50512-0_35 · Cited by 3
Self-citationGarcía, M. C. (2019) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v30i148.122 · Cited by 3
“En otro ensayo (13) estas diferencias no fueron significativas pero sí numéricas (n=29).”
BackgroundInfluentialSchmeck, K., & Romanos, M. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_21 · Cited by 1
Gillavry, D. W. M., & Ullrich, D. C. (2020) · Military Psychology · doi:10.1080/08995605.2020.1730111 · Cited by 1
“…treatment of dissociative symptoms in borderline personality disorder (Bandelow, Schmahl, Falkai, & Wedekind, 2010; Philipsen, Schmahl, & Lieb, 2004; Schmahl et al., 2012) and PTSD (Lubin, Weizman, Shmushkevitz, & Valevski, 2002), and it, therefore, stands to reason that β-endorphin plays a role…”
Kein Effekt auf dissoziative Symptome?
Broocks, A. (2012) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-012-0213-9
Behandlung von Persönlichkeits- und Verhaltensstörungen
Rentrop, M. (2015) · Springer eBooks · doi:10.1007/978-3-7091-1849-8_5
Zerebrale Angiomatose und Borderline-Störung
Bernard, F., & Röpke, S. (2012) · NeuroTransmitter · doi:10.1007/s15016-012-0566-9
Stellenwert des Opioidantagonisten Naltrexon bei stationär behandelten Borderline-Patienten
Meiser, M. (2016) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-5868
Psychopharmacologie du trouble de la personnalité borderline
Perroud, N. A. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-76266-6.00010-0
PSYCHOLOGICAL FEATURES OF PEOPLE WITH BORDERLINE PERSONALITY DISORDERS
Morozova, V. S. (2018) · Bulletin of Taras Shevchenko National University of Kyiv Series “Psychology” · doi:10.17721/bsp.2018.2(9).12
Basic mechanisms of, and treatment planning/targets for, personality disorders
Saunders, K., & Pearce, S. (2020) · doi:10.1093/med/9780198713005.003.0118 · Cited by 1
Schmahl, C. G. (2013) · Springer eBooks · doi:10.1007/978-3-642-35068-9_4
Self-citationSchmahl, C. G. (2019) · Springer eBooks · doi:10.1007/978-3-662-58470-5_6 · Cited by 1
Self-citationSchmahl, C. G. (2022) · Springer eBooks · doi:10.1007/978-3-662-64057-9_6
Self-citationPharmakotherapeutische Ansätze
Priebe, K., Schmahl, C. G., & Stiglmayr, C. (2013) · Springer eBooks · doi:10.1007/978-3-642-35066-5_9
Self-citationDissoziative Störungen (Konversionsstörungen) (F44)
Weber-Papen, S., Mathiak, K., & Schneider, F. W. (2016) · Springer eBooks · doi:10.1007/978-3-662-50345-4_26
Macchia, A., Malejko, K., & Abler, B. (2023) · Nervenheilkunde · doi:10.1055/a-2016-2551
Grundlagen der Diagnostik und Therapie
(2024) · Elsevier eBooks · doi:10.1016/b978-3-437-22487-4.16001-0
Gescher, D. M., Vavra, P., Schanze, D., Zenker, M., Witt, S. H., Frodl, T., & Schmahl, C. G. (2025) · Research Square · doi:10.21203/rs.3.rs-7489711/v1
Self-citationMiller, C. O. G. (2025) · Springer eBooks · doi:10.1007/978-3-032-13315-1_3
Biermann, M., & Schmahl, C. G. (2026) · Psychotherapie: Praxis · doi:10.1007/978-3-662-72268-8_94
Self-citationMiño-Reyes, V., Larenas-Matta, P., Quijada-Leyton, M. J., & Nvo-Fernández, M. (2026) · European Journal of Trauma & Dissociation · doi:10.1016/j.ejtd.2026.100763 · Cited by 1
Metadata
- Authors
- Schmahl, C., Kleindienst, N., Limberger, M., Ludäscher, P., Mauchnik, J., Deibler, P., Brünen, S., Hiemke, C., Lieb, K., Herpertz, S., Reicherzer, M., Berger, M., & Bohus, M.
- Affiliations
- Central Institute of Mental Health (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- Corresponding author
- Schmahl, Christian
- Kleindienst, Nikolaus
- ORCID
- Venue
- International Clinical Psychopharmacology
- Published
- 2012-01
- Volume
- 27
- Issue
- 1
- Pages
- 61-68
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2320426285
- Cited by
- 63
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 2 · 2019: 11 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 2
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- naltrexone, borderline personality disorder, dissociative symptoms, pharmacotherapy
- MeSH terms
- Adolescent, Adult, Borderline Personality Disorder, Double-Blind Method, Female, Germany, Humans, Naltrexone, Narcotic Antagonists, Placebos, Psychiatric Status Rating Scales, Time Factors, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.